Kobo Biotech Ltd-$

Kobo Biotech Ltd. has submitted its Annual Report for the Financial Year 2024-25, as per Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is currently under Corporate Insolvency Resolution Process (CIRP) following an application by JM Financial Asset Reconstruction Company Limited. Ms. Namrata Amol Randeri has been appointed as the Resolution Professional and is managing the company's affairs. The report includes sections on corporate information, notice of the AGM, report of the Resolution Professional, Directors' Report, secretarial and auditor's reports, and financial statements. The 32nd Annual General Meeting is scheduled for July 24, 2026, to adopt the audited financial statements.

Kobo Biotech Ltd has filed its Annual Report for the Financial Year 2023-24, as per SEBI regulations. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) following an application by JM Financial Asset Reconstruction Company Limited. Ms. Namrata Amol Randeri has been appointed as the Resolution Professional and is managing the company's affairs. The 31st Annual General Meeting is scheduled for July 24, 2026, to adopt the audited financial statements and related reports. The Board of Directors' powers remain suspended and are exercised by the Resolution Professional.

Kobo Biotech Ltd is holding its 32nd Annual General Meeting (AGM) on July 24, 2026, via Video Conferencing. The AGM will focus on adopting the Audited Financial Statements for the financial year ended March 31, 2025, along with the reports from the Resolution Professional and Statutory Auditors. The company is currently under Corporate Insolvency Resolution Process (CIRP) following an application by JM Financial Asset Reconstruction Company Limited. Ms. Namrata Amol Randeri is the appointed Resolution Professional, managing the company's affairs as a going concern under the supervision of the Committee of Creditors.

Kobo Biotech Ltd announced its 31st Annual General Meeting (AGM) will be held on July 24, 2026, at 10:00 AM IST via Video Conferencing/Other Audio Visual Means (VC/OAVM). The company is currently under Corporate Insolvency Resolution Process (CIRP) following an order dated August 13, 2024. Ms. Namrata Amol Randeri has been appointed as the Resolution Professional and will be exercising the powers of the Board of Directors. The AGM will focus on adopting the audited financial statements for the financial year ended March 31, 2024, along with the reports of the Resolution Professional and Statutory Auditors.

Kobo Biotech Ltd has announced the closure of its trading window for dealing in the company's securities by insiders. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from July 1st, 2026, and will reopen 48 hours after the declaration of the Un-Audited Financial Results for the first quarter ending June 30th, 2026. The specific date for the Board meeting to consider these financial results will be intimated separately.

The National Company Law Tribunal (NCLT) has approved the resolution plan submitted by Beaufond Industries Limited for Kobo Biotech Limited. The resolution plan was initially approved by the Committee of Creditors on March 17, 2026, and subsequently submitted to the NCLT. As per the last audited financial statements, Kobo Biotech's net worth was ₹132.91 crores and total assets were ₹71.39 crores as of March 31, 2024. Beaufond Industries' net worth was ₹333.18 crores as of March 31, 2025, which will be merged with Kobo Biotech as part of the approved resolution plan.

The National Company Law Tribunal (NCLT), Hyderabad Bench-I, approved the resolution plan for Kobo Biotech Limited submitted by Beaufond Industries Limited under Section 31 of the Insolvency and Bankruptcy Code, 2016. The resolution plan, approved by the Committee of Creditors with 100% voting share, contemplates the acquisition of Kobo Biotech as a going concern, including restructuring and revival of business operations. Key features include reduction of existing share capital, issue of fresh equity shares, retention of minimum public shareholding, and a composite scheme of amalgamation and arrangement.

Kobo Biotech Limited has officially confirmed that as of March 31, 2026, the company does not fall under the category of a 'Large Corporate (LC)'. This determination is based on the framework and applicability criteria outlined in SEBI Circulars SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. This intimation means Kobo Biotech is not subject to the specific disclosure requirements related to fund-raising by issuance of debt securities applicable to large entities.

Kobo Biotech Ltd. has announced the closure of the trading window for insiders in accordance with the SEBI (Prohibition of Insider trading) Regulations, 2015. The closure will be effective from April 1, 2026, until the end of 48 hours after the declaration of the audited financial results for the quarter and year ending on March 31, 2026. The trading window will reopen after the 48-hour period. The date of the board meeting to consider the audited financial results will be intimated separately.

The 15th meeting of the Committee of Creditors (CoC) of Kobo Biotech Limited was held on Wednesday, 1st October, 2025 at 03:45 p.m. The meeting was conducted via video conferencing and attended by J M Financial Asset Reconstruction Company Ltd, holding 99.12% voting share. The draft Minutes, voting sheet, CIRP cost sheet, draft RFRP with Evaluation Matrix were circulated to the CoC Members on 3rd October, 2025. The voting period begins on 3rd October, 2025 and ends on 8th October, 2025 at 05:00 pm.